Real-life drug retention rate and safety of rituximab when treating rheumatic diseases: a single-centre Swiss retrospective cohort study

Real-life drug retention rate and safety of rituximab when treating rheumatic diseases: a single-centre Swiss retrospective cohort study

Abstract Background In Switzerland, rituximab (RTX) is licenced for the treatment of rheumatoid arthritis (RA) and ANCA-associated vasculitis (AAV) but is frequently used off-label to treat other auto-immune diseases (AID), especially connective tissue diseases (CTD). We aimed to characterise the us...

Full description

Bibliographic Details
Main Authors: Alexandre Dumusc, Fahad Alromaih, Matthieu Perreau, Thomas Hügle, Pascal Zufferey, Diana Dan
Format: Article
Language:English
Published: BMC 2023-06-01
Series:Arthritis Research & Therapy
Subjects:
Rituximab
Off-label
Auto-immune diseases
Drug retention rate
Rheumatoid arthritis
Connective tissue disease
Online Access:https://doi.org/10.1186/s13075-023-03076-w

Internet

https://doi.org/10.1186/s13075-023-03076-w

Similar Items